Feasibility and efficacy of delayed pharmacoinvasive therapy for ST-elevation myocardial infarction

Table 2 Outcomes based on primary and secondary endpoints in the two study groups

Clinical outcome	Routine (n = 183)	Delayed (n = 154)	P value
Primary endpoints, n (%)
MACCE	16 (8.7)	20 (12.9)	0.152
Secondary endpoints, n (%)
Death	5 (2.7)	3 (1.9)	0.732
Myocardial infarction	2 (1.1)	7 (4.5)	0.085
Target vessel revascularization	3 (1.6)	3 (1.9)	0.999
Congestive heart failure	6 (3.3)	7 (4.5)	0.547
Stroke	0	0	0.999
Angina	4 (2.2)	1 (0.6)	0.381
Dyspnea	6 (3.3)	5 (3.2)	0.999
Major Bleeding1	1 (0.5)	3 (1.9)	0.335

¹As defined by Bleeding Academic Research Consortium (BARC) classification.

MACCE: Major adverse cardiac and cerebrovascular events.